Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT00028600
- Locations
- 🇺🇸
Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States
🇺🇸Union Hospital Cancer Program at Union Hospital, Elkton MD, Maryland, United States
🇺🇸CCOP - Christiana Care Health Services, Newark, Delaware, United States
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: imatinib mesylateDrug: methotrexateDrug: vincristine sulfateDrug: leucovorin calciumProcedure: peripheral blood stem cell transplantationProcedure: autologous hematopoietic stem cell transplantationProcedure: allogeneic hematopoietic stem cell transplantationRadiation: total-body irradiationDrug: tacrolimusBiological: filgrastimDrug: etoposideDrug: cyclophosphamideDrug: cytarabineOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00039377
- Locations
- 🇺🇸
Great Falls Clinic, Great Falls, Montana, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
- Conditions
- Interventions
- Biological: sargramostimDrug: cyclophosphamideDrug: asparaginaseDrug: cytarabineDrug: dexamethasoneDrug: daunorubicin hydrochlorideDrug: etoposideDrug: imatinib mesylateDrug: leucovorin calciumDrug: mercaptopurineDrug: methotrexateDrug: prednisoneDrug: thioguanineDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationRadiation: radiation therapyProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 1929
- Registration Number
- NCT00002514
- Locations
- 🇺🇸
Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States
🇺🇸MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸Swedish Medical Center, Englewood, Colorado, United States
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 105
- Registration Number
- NCT00039130
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 4
- Registration Number
- NCT00006747
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
- First Posted Date
- 2003-01-08
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00051311
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00001498
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 40
- Registration Number
- NCT00001677
- Locations
- 🇺🇸
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, Maryland, United States
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1250
- Registration Number
- NCT00048568
- Locations
- 🇺🇸
Local Institution, Milwaukee, Wisconsin, United States
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00038610
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.